Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Cytek Biosciences Inc(CTKB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CTKB
09/25/2026: CTKB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Cytek Biosciences is a life sciences tools company that has gained recognition for its innovative Full Spectrum Profiling cytometry platforms. The company’s primary strength lies in its specialized Aurora and Northern Lights systems, which provide high-resolution cell analysis that outpaces many traditional methods. While Cytek has a significant growth opportunity in transitioning its technology into the clinical diagnostics market, it faces stiff competition from entrenched industry leaders like Becton Dickinson. Retail investors should monitor the company's ability to maintain revenue growth amid fluctuating biotech R&D budgets and manage its regulatory path. Cytek is best suited for growth-oriented investors capable of managing the volatility inherent in early-stage medical technology stocks.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in a high-growth sector of life sciences with proprietary technology that commands a premium. |
| Momentum investor | Mixed fit | Momentum fit is conditional on a positive Upturn signal as the stock often reacts to biotech spending trends. |
| Value investor | Weak fit | The company's current valuation remains driven by growth expectations rather than established earnings multiples. |
| Dividend investor | Weak fit | The company does not pay a dividend and prioritizes capital reinvestment. |
| Low-risk investor | Weak fit | Small-cap life science stocks are subject to significant volatility and business execution risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a smaller-cap growth stock, share prices are subject to significant swings based on industry sentiment. |
| Valuation risk | Medium / high | High growth multiples can contract rapidly if revenue growth expectations are not met. |
| Competition risk (incumbent diagnostics) | High | Established players like Becton Dickinson have significant resources to protect their market share. |
| Business quality | Medium | The core technology is strong, but the business is still building global commercial scale. |
| Dividend income | Low / none | Income-focused investors will not find this stock suitable for dividends. |
| Execution risk | Medium | Success depends on effectively scaling operations and securing clinical adoption. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -25.65% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 744.80M USD | Price to earnings Ratio - | 1Y Target Price 5.56 |
Price to earnings Ratio - | 1Y Target Price 5.56 | ||
Volume (30-day avg) 1.1M shares | Beta 1.19 | 52 Weeks Range 3.28 - 6.18 | Updated Date 09/25/2026 |
52 Weeks Range 3.28 - 6.18 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Instruments | Revenue from the sale of Aurora, Northern Lights, and imaging systems. | This is the primary revenue driver, representing sales of high-tech laboratory hardware. |
| Reagents and Consumables | Sales of cFluor reagents and specialized assays used with the instruments. | This segment provides recurring revenue that grows as the installed base of instruments expands. |
| Services and Support | Maintenance contracts, training, and technical support services. | Provides stable, long-term cash flow after the initial instrument purchase. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 502.76M | Price to Sales(TTM) 3.6 |
Enterprise Value 502.76M | Price to Sales(TTM) 3.6 | ||
Enterprise Value to Revenue 2.43 | Enterprise Value to EBITDA 222.69 | Shares Outstanding 129.98M | Shares Floating 102.94M |
Shares Outstanding 129.98M | Shares Floating 102.94M | ||
Percent Insiders 8.47 | Percent Institutions 63.05 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Cytek Biosciences Inc
Exchange NASDAQ | Headquarters Fremont, CA, United States | ||
IPO Launch date 2021-07-23 | President, CEO & Chairman of the Board Dr. Wenbin Jiang Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 682 | Website https://cytekbio.com |
Full time employees 682 | Website https://cytekbio.com | ||
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.